drugset / Trial / NCT00425334

Safety Study of Hemospan® in Prostatectomy Patients

NCT00425334

Phase 2 Completed 20 enrolled Sangart
RandomizedSingle-groupSingle-blindTreatment

Summary

This is a progressive dose escalation study designed to evaluate the safety of Hemospan compared to a standard crystalloid solution (Ringer's lactate) in elective surgery patients undergoing total prostatectomy procedures with anticipated blood loss of more than 500 mL. Secondary objectives of this study are to observe possible activity of Hemospan for tissue oxygenation, perfusion and cardiovascular support.

Timeline

Start
2005-07
Primary completion
2007-10
Completion
2007-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hemospan Protein / enzyme biologic 250 ml
Subject Hemospan Protein / enzyme biologic 500 ml
Comparator Ringer's Lactate Other / unclassified 250 ml
Comparator Ringer's Lactate Other / unclassified 500 ml

Indications